Home Tags Bristol Myers Squibb
Tag: Bristol Myers Squibb
Berenberg Bank a réduit son objectif de cours sur Bristol-Myers Squibb de 75 $ à 71,00 $ et a fixé une note d'« achat » pour la société dans un rapport de recherche publié lundi.
Bristol-Myers Squibb (BMY) and Pfizer (PFE) have recognized the latest court ruling confirming the patents for the oral anticoagulant Eliquis ...
AbbVie (ABBV) has exercised its exclusive right to acquire TeneoOne and its principal asset, TNB-383B, based on an interim analysis of an ongoing Phase 1 study. TeneoOne is a ...
The global ophthalmic melanoma drug market is expected to grow at a significant CAGR over the forecast period
. . «Un aperçu du marsché de analysis of the pipeline de medicaments en oncologie et the perspectives de croissance Report on the analysis of the pipeline of the media and oncology against the...
Pharmaceutical giant Bristol-Myers Squibb Co (NYSE: BMY) is gaining momentum, as company announces multibillion-dollar deal to buy cardio-focused biopharmaceutical Myokardia Inc (NASDAQ: MYOK)
Bristol Myers Squibb has reached a deal to acquire MyoKardia for $ 13 1 billion The all-cash takeover will see Bristol Myers pay a 61% premium over MyoKardia's closing price on Friday to secure a heart disease drug that's on the market point to be submitted for approval
MydoKardia's experimental cardiac treatment, Mavacamten, received a "breakthrough therapy designation" from the US Food & Drug Administration in July of this year
US drugmaker Bristol-Myers Squibb said Monday it would buy heart drug developer MyoKardia for around $ 13 billion
Bristol Myers Squibb, a producer of cancer drugs, said it would buy biotech MyoKardia for $ 13 billion in all-cash transactions to expand its line of heart drugs